RB Capital Management LLC Cuts Position in Pfizer Inc. $PFE

RB Capital Management LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 5.7% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,822 shares of the biopharmaceutical company’s stock after selling 709 shares during the period. RB Capital Management LLC’s holdings in Pfizer were worth $300,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. grew its position in Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK grew its position in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer in the first quarter worth $8,283,000. Alta Advisers Ltd grew its position in Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC grew its position in Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company’s stock worth $3,176,000 after acquiring an additional 10,051 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock opened at $24.97 on Wednesday. The company has a market cap of $141.94 billion, a P/E ratio of 13.28, a PEG ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a 50-day moving average of $24.74 and a 200 day moving average of $24.39.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

Several analysts have weighed in on PFE shares. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Redburn Atlantic lowered their price objective on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. Wolfe Research upped their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research note on Wednesday, April 30th. Finally, Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.